LeukoStrat® CDx FLT3 Mutation Assay

90574

2 mL whole blood collected in a sodium heparin (green-top) tube or EDTA (lavender-top) tube

1 mL whole blood • 0.25 mL bone marrow

0.5 mL bone marrow collected in a sodium heparin (green-top) tube or EDTA (lavender-top) tube

Include patient's date of birth and specimen source on test request form and specimen container.
Submit blood and bone marrow samples within 7 days of collection. Primary samples received after 7 days of collection will be run with a disclaimer, but if the sample is QNS, the lab will charge for testing. Primary samples that are older than 14 days will not be tested.

Vendor does not accept samples Saturday, Sunday or holidays.

Sodium heparin (green-top) tube

Room temperature

Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable

Mon-sat

See Laboratory Report

The fms related tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML), occurring in approximately 30% of patients at the time of diagnosis. Although generally associated with normal cytogenetics where patients have standard risk of relapse, FLT3 mutations have also been identified in sub-groups of patients with chromosomal abnormalities that are associated with high risk of disease relapse.
The LeukoStrat CDx FLT3 Mutation Assay is an IVD companion diagnostic to aid in the selection of acute myeloid leukemia (AML) patients eligible for treatment with midostaurin (US, EU) or gilteritinib fumarate (Japan, US, EU), or quizartinib hydrochloride (Japan).